Gandeeva Therapeutics’ Post

What's to come in 2024 - check out this summary of the latest trends and developments for life science companies.

9 lessons learned from AACR24 The AACR annual meeting is a wonderful opportunity to challenge established paradigms, as well as scientific dogma. These meetings are often overwhelming as the sheer volume and velocity of data hits daily like a tsunami. By the end of the meeting many are left with the all too familiar residues of brain fog and jet lag.  We're highlighting some key learnings we've taken from the conference in San Diego, which others in oncology new product development might well want to think about. Agree or disagree, part of what we do at BSB is to challenge your thinking. Here we consider what we can learn – both good and bad – from researchers, industry executives, thought leaders, and regulatory agencies. There's certainly been a lot of inspiring science on show at AACR24. In Part One of Lessons Learned we discuss nine topics in an easy to read format. The key scientific lessons will follow in Part Two next week... Check it out! https://lnkd.in/eN-9EzAJ

Details of The Labour Party life science plan are emerging...what jumps out to LifeArc? 1/6 - Make life science a priority for DHSC 🏥 LifeArc drives basic science towards patients. Coordination between science and healthcare is vital - inc in Government. Peter Kyle Wes Streeting MP 2/6 Increase uni spinouts 🎓 🤝 LifeArc shared expertise with the recent review of spinouts, and we're supporting next steps. We're keen to ensure future initiatives reflect the needs of all the players involved, and crucially helps more health innovations reach patients faster. 3/6 Increase 'access to finance' 💷 The easier and more attractive we make it for life science companies to start, scale and stay in the UK, the better chance we have of improving patients’ lives with new innovations and maintaining the UK’s leading role in life sciences. LifeArc was active in shaping the Mansion House compact agreed by the current Government. We'll work with the next Government – whoever they are – to ensure the Compact boosts UK companies. The life sciences industry needs to demonstrate its strengths as an attractive investment – an area where LifeArc Ventures plays a key role. 4/6 Maintain R&D tax credits, review them, maintain patent box 💡 These schemes make it less expensive to do life science research in the UK - especially for the small innovative companies we work with through LifeArc Ventures. Labour saying they'll prioritise life sciences in their review of credits - great to see, given life science SMEs are uniquely dependent on them for extensive periods of 'risky' R&D. 5/6 set out key technologies for the UK to lead, including (maybe) cell and gene therapies (CGT) 🔬 CGT is very exciting and we published on the skills the UK needs to keep them accelerating ( https://lnkd.in/enwaApjq ). It's important the next Government - whoever they are - keeps this sector growing. 6/6 Much more (regulation, planning reform, skills, NHS trials, trade strategy) 🏗 LifeArc is active in all these areas and look forward to sharing 25yrs expertise to help inform decisions to support UK life sciences and drive more innovative health research to patients.

Early bird rates end June 3 for BioCentury Grand Rounds – an R&D conference in Nashville for academic innovators, researchers, investors and industry leaders to explore the translational science behind the next wave of biotech breakthroughs and the people driving them. Take advantage of these special rates and make connections with peers across the biopharma sphere as we discuss: ➤ What Investors Want: Gain insights from top investors on what they’re looking for in today’s market.   ➤ New Investible Space: Discover emerging sectors and opportunities that are catching the eye of investors.   ➤ Measurements of Translational Success: Learn how to measure and showcase the impact of your innovations. Register now to secure your spot at #BioCenturyGrandRounds: https://loom.ly/yydzbC8 Submit your nominations to join the Presenting Companies Class of 2024 by June 3 to lock in early bird rates: https://loom.ly/GHHuDog #GrandRounds #BiotechBreakthroughs #researchdevelopment #academia #venturecapital #biotech #drugdiscovery #drugdevelopment #RnD

We’re excited to attend BioCentury Inc’s Grand Rounds conference next week in Nashville! The latest episode of BioCentury This Week gave us a sneak peek into the powerhouse lineup and key trends that will be highlighted. https://lnkd.in/gMpBFciP Hosting this conference in Nashville is significant to us at the CBC, as it underscores the high-impact scientific research happening in the Midwest and our commitment to accelerating the translation of these projects. We're particularly excited by McKinsey & Company’s report preview by Guang Yang, which tackles crucial questions like: "How can we overcome bottlenecks in the translation process?", "Is funding reaching the most translatable experiments?", and "How can we shorten timelines to bring innovations to market?" These are core challenges that the CBC is actively addressing through our model and processes. We are proud to have BioCentury as a supporting organization for our upcoming BioCapital Summit in November, and we’re eager to continue the critical discussions and build on the momentum from Grand Rounds. Learn more about our exclusive BioCapital Summit here: https://lnkd.in/gXziGSA4

"An expert is a person who has made all the mistakes that can be made in a very narrow field." - Niels Bohr Symeres is dedicated to fostering collaboration and knowledge-sharing within the scientific community, and we're excited to support initiatives that promote continuous learning and development. That’s why we are thrilled to share that Symeres is proudly sponsoring an upcoming virtual event hosted by EFMC Young Scientists Network MedChemBio, focusing on the intriguing topic of 'Knowledge Creation from Failure'.   Date: March 26, 2024 Time: 16:30 to 18:30 HRS. CET   In today's dynamic landscape, embracing failure as a vital part of the learning process is paramount. This event promises to delve deep into the invaluable insights gained from setbacks, paving the way for innovation and growth within the realm of medicinal chemistry and biology.   We have a fantastic line-up of speakers and panelists e.g.: Gebhard Thoma of Novartis, Daniel Rauh of the TU Dortmund University, Stéphanie Guéret of AstraZeneca, and Tilly (Matilda) Bingham of Cumulus Oncology.    Save the date, mark your calendars, and register now via the link below to secure your spot at this enriching event! Let's unlock the power of failure together and propel our industry forward. Registration to the event is free and open to all. https://lnkd.in/dsXxDA5e   #EFMC #MedChemBio #VirtualEvent #Innovation #Science #Learning #Failure #Collaboration #Symeres #MakingMoleculesMatterTogether

LVGEA believes biotech companies can thrive in Las Vegas, which is why we've made it one of our target industries. One asset in the region is Roseman University of Health Sciences, which offers 50k square feet of research and wet lab space at its Summerlin campus. Read more about how Roseman is working with LVGEA to attract biotech companies to the region: https://bit.ly/47LqhYW

Are you looking to expand your life science operations into the #UnitedStates? Frederick County, Maryland offers a strategic location for your next office. Here’s why: 1. Proximity to Innovation: Frederick County is home to the National Cancer Institute (NCI) at Fort Detrick, a global leader in oncology, infectious diseases, and biodefense research. This proximity fosters collaboration opportunities with leading researchers and access to state-of-the-art facilities. 2. Skilled Workforce: With a rich talent pool from local universities like Hood College and Mount St. Mary's University and proximity to the Baltimore-Washington metro area, Frederick County offers access to a highly educated and specialized workforce crucial for advancing your life science work. 3. Business-Friendly Environment: The county provides a supportive ecosystem for businesses, including a soft landing program and incentives tailored to foster innovation in biotechnology and pharmaceutical sectors. 4. Infrastructure and Connectivity: Situated near major transportation routes like Interstates 70 and 270, Frederick County ensures seamless connectivity to major East Coast markets and 3 international airports, facilitating efficient logistics and distribution. If you’re considering a strategic move into the #USA life sciences market, #FrederickCountyMD should undoubtedly be on your list. Our strategic advantages and supportive ecosystem can propel your business to new heights in life sciences like the companies in the article below! Let’s explore how Frederick County can be the perfect launchpad for your next phase of growth! Feel free to stop by #SelectUSA #Maryland #Booth202 for more information or to discuss potential opportunities. #LifeSciences #Biotechnology #Pharmaceuticals #Innovation #FrederickCounty #BusinessExpansion #Global

There IS a special relationship between the UK and US in at least one significant area of trade – the life sciences. This may not be quite as powerful as a genuine trade alliance between the White House & Westminster, but when biotech chiefs in the territories don’t let the Atlantic get in the way of business, then the Charles River is a mere hop, step and a jump! Cambridge UK companies continue to find facilities, boots on the ground and an environment geared to growth when they put down roots in Greater Boston and wider Massachusetts – most notably in the field of BioMedTech. No-one appears to challenge the claim by Massachusetts to be home to the top life sciences cluster in the world. Companies based there enjoy a range of advantages including a thriving life sciences community, highly educated workforce, world-leading universities and hospitals, access to an array of economic development programs that support large and small biotechnology companies, and tax benefits. From biotech-zoned science parks to robust infrastructure and pre-permitted biotech sites, Massachusetts reckons it has it all for companies looking for space. And the number of Cambridge UK biotechs based there would appear to agree. In this article – https://lnkd.in/eTri3utE – we take a look at some of the Cambridge UK companies with operations in the State including: abcam, Alchemab Therapeutics Ltd, Apollo Therapeutics, AstraZeneca, Bicycle Therapeutics, Cambridge Cognition, Cerevance, Cresset Biomolecular Discovery, Cycle Pharmaceuticals, Domainex, Dunad Therapeutics, Eleven Therapeutics, Lightcast, NodThera, Nuclera, Quotient Therapeutics and Transition Bio, Inc. • Earlier this year, Cambridge and UK Life Science gateway One Nucleus held its 2024 Boston Bootcamp competition with the winners Carocell Bio, ENHANC3D GENOMICS, ikarovec and STORM Therapeutics Limited rewarded with a trip to Boston in April. One Nucleus is planning a return delegation to Boston in September to incorporate a pitching day within Biotech Week Boston.

New on Lab Insights: Wesley Wong, Consulting Team Manager at Roche Diagnostics APAC, interviews Professor Tony Badrick , CEO of The Royal College of Pathologists of Australasia (RCPA) and current Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) president, where he outlines the environmental challenges faced by clinical labs today, why clinical labs should address it, and why it may not be as difficult as one might think. https://lnkd.in/gH9t7BcS